重组长效人精氨酸酶抑制肿瘤细胞生长的研究

 目的 研究重组长效人精氨酸酶对黑色素瘤、喉癌和肝癌等肿瘤细胞的抑制效果,探讨该酶作为抗癌药的应用前景.方法 以离体培养的6株肿瘤细胞(人黑色素瘤细胞MV3、 M14、A875、A375,喉癌细胞Hep2和人肝癌细胞HepG2)为实验对象,培养至90%汇片时收获细胞,转种到96孔板,加入不同浓度的重组长效人精氨酸酶共同培养72 h.采用MTT法,测定重组长效人精氨酸酶对肿瘤细胞生长的抑制情况.结果 所有被测细胞的活力随着该酶浓度的增加而降低,且该酶对两株黑色素瘤细胞的IC50小于0.1 U/ml.被测药物对人肝癌细胞HepG2的IC50是0.835 U/ml,对人喉癌细胞Hep2的IC50是2.269 U/ml.结论 重组长效人精氨酸酶对体外培养的黑色素瘤、喉癌和肝癌细胞具有细胞毒性,是有潜力的抗癌药物候选物.

Recombinant long-acting human arginase inhibits the in vitro proliferation of tumor cells

Objective To study the effect of recombinant long - acting human arginase on tumor cell proliferation and to evaluate its significance in biopharmaeeutieal practice. Methods Six established human tumor cell lines （human melonoma MV3, M14 A875 ,A375, human laryngeal cancer Hep2 and human hepatocellular carcinoma cell HepG2） were used. Cells were grown to 90% confluence, harvested, and plated in a 96 - well plate and co - cultured with increasing concentrations of recombinant long - acting human arginase for 72 hours. MTr assay was used to measure percent viability. Results All cell lines demonstrated decreased viability as concentrations of recombinant long - acting human arginase increased. Two of the four melanoma cell lines had IC50 values 〈 0.1 U/ ml. Human laryngeal cancer Hep2 and human hepatocellular carcinoma cell HepG2 had an IC50 value of 2.269 U/ml and 0.11 U/ml, respectively. Conclusions Recombinant long - acting human arginase is cytotoxie to melanoma cells, human laryngeal cancer cells and human hepatoeellular carcinoma cells in vitro. It is a promising novel agent for treatment of cancer.